Sort by
Refine Your Search
-
Listed
-
Program
-
Field
-
to optimization algorithms Other closely related topics Your profile Master's degree in computer science, physics or a related field Advanced knowledge in the field of Quantum Computing Knowledge of Python Good
-
various disciplines: computer scientists, mathematicians, biologists, chemists, engineers, physicists and clinicians from more than 50 countries currently work at the LCSB. We excel because we are truly
-
molecular targets critical for developing new therapies for rare diseases, based on genetic data and biological system simulations. -Computational Drug Repurposing: Developing novel algorithms and databases
-
well as computational modeling. The development and numerical implementation of novel methods has become a key issue in modern oncology, both in terms of understanding the biology of cancers and for medical oncology
-
establishments (Université Côte d'Azur, CNRS, INRAE, INSERM ...), but also with the regiona economic players. With a presence in the fields of computational neuroscience and biology, data science and modeling
-
in all areas · Personalized learning programme to foster our staff’s soft and technical skills · Multicultural and international work environment with more than 50 nationalities
-
be expected to teach advanced courses in Artificial Intelligence—particularly in machine learning, statistical learning, natural language processing (NLP), symbolic AI, computer vision, and related
-
We are recruiting a highly motivated and experienced researcher to develop and structure a research and educational program dedicated to kidney cancer. The position is supported by a 3-5 year fixed
-
close as possible to tumor sites to deliver its high-energy radioactive radiation, allowing the destruction of targeted the cells. Research program: Belonging to the halogen series, astatine exhibits in
-
pool of leukemic cells in sanctuary lymphoid organs leading to transformation in high-grade lymphomas. 3) the elaboration of computational prediction tools of progression and new preclinical models